Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)

被引：0
|
作者：
Stenehjem, David D.
Parikh, Kinjal
Batten, Julia Anne
Van Atta, Joan
Crispin, Hilda
Sageser, Daniel S.
Grossmann, Kenneth F.
Wang, Junfeng
Tantravahi, Srinivas Kiran
Samlowski, Wolfram E.
Agarwal, Neeraj
机构：
[1] Univ Utah, Coll Pharm, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT 84112 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
476
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma
    Tasha Hughes
    Matthew Klairmont
    Joseph Broucek
    Gail Iodice
    Sanjib Basu
    Howard L. Kaufman
    Cancer Immunology, Immunotherapy, 2015, 64 : 459 - 465
  • [32] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma
    Powell, S. F.
    Dudek, A. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.
    Buchbinder, Elizabeth Iannotti
    Dutcher, Janice P.
    Perritt, Jessica C.
    Clark, Joseph
    Holtan, Shernan G.
    Kirkwood, John M.
    Curti, Brendan D.
    Lao, Christopher D.
    Kaufman, Howard
    Fishman, Mayer N.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Sequential Immune Monitoring of Melanoma and Renal Cell Carcinoma Patients Treated with High-dose Interleukin-2 (IL-2): Immune Patterns and Prognosis
    Foureau, D. M.
    Amin, A.
    Norton, H.
    Sarantou, T.
    McKillop, I. H.
    White, R. L.
    Salo, J. S.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S116 - S116
  • [35] Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment- naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial
    Procopio, Giuseppe
    Verzoni, Elena
    Bracarda, Sergio
    Ricci, Sergio
    Ridolfi, Laura
    Sacco, Cosimo
    Miceli, Rosalba
    Porta, Camillo
    Bregni, Marco
    Bajetta, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [36] Durability of responses in patients with metastatic renal cell carcinoma treated with high dose lnterleukin-2 (HD IL-2)
    Clark, Joseph I.
    Morse, Michael A.
    Wong, Michael K. K.
    Mcdermott, David F.
    Kaufman, Howard L.
    Daniels, Gregory A.
    Perritt, Jessica C.
    Hua, Hong
    Aung, Sandra
    BJU INTERNATIONAL, 2015, 116 : 6 - 6
  • [37] Assessment of absolute lymphocyte count (ALC) as a predictor of progression-free survival (PFS) and overall response rate (ORR) in metastatic melanoma (MM) patients (pts) treated with high-dose interleukin-2 (HD IL-2)
    Yorio, Jeffrey Thomas
    Fox, Patricia S.
    Joseph, Richard Wayne
    Bassett, Roland
    Davies, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
    Buchbinder, Elizabeth I.
    Dutcher, Janice P.
    Daniels, Gregory A.
    Curti, Brendan D.
    Patel, Sapna P.
    Holtan, Shernan G.
    Miletello, Gerald P.
    Fishman, Mayer N.
    Gonzalez, Rene
    Clark, Joseph I.
    Richart, John M.
    Lao, Christopher D.
    Tykodi, Scott S.
    Silk, Ann W.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [39] High-dose interleukin-2 in metastatic disease: Renal cell carcinoma and melanoma
    Dutcher, J
    ONCOLOGY-NEW YORK, 2002, 16 (11): : 3 - 3
  • [40] HIGH-DOSE INTERLEUKIN-2 IN THE THERAPY OF METASTATIC RENAL-CELL CARCINOMA
    PARKINSON, DR
    SZNOL, M
    SEMINARS IN ONCOLOGY, 1995, 22 (01) : 61 - 66
12345